Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 743

1.
2.

Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.

DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, DeCaro M, Ruggiero N, Singhal S, Greenspon A.

Pharmacotherapy. 2007 May;27(5):691-6.

PMID:
17461704
3.

Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.

Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK.

J Invasive Cardiol. 2006 Apr;18(4):162-4.

PMID:
16729401
4.

Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?

Hermosillo AJ, Spinler SA.

Ann Pharmacother. 2008 Jun;42(6):790-805. doi: 10.1345/aph.1K591. Review. Erratum in: Ann Pharmacother. 2008 Oct;42(10):1521.

PMID:
18477734
5.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators..

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
6.

Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.

Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB.

Am Heart J. 2004 Mar;147(3):463-7.

PMID:
14999195
7.

Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?

Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D; GRACE Investigators..

Eur Heart J. 2007 Jul;28(14):1717-22.

8.
9.
10.

Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.

Uchida Y, Mori F, Ogawa H, Takagi A, Hagiwara N.

J Cardiol. 2010 May;55(3):362-9. doi: 10.1016/j.jjcc.2009.12.014.

11.

Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.

Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, Alexander KP.

Am J Med. 2012 Sep;125(9):897-905. doi: 10.1016/j.amjmed.2012.04.006.

PMID:
22795814
12.

Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.

Herlitz J, Holm J, Peterson M, Karlson BW, Haglid Evander M, Erhardt L; LoWASA study group..

Eur Heart J. 2004 Feb;25(3):232-9.

13.

Major bleeding in hemodialysis patients.

Holden RM, Harman GJ, Wang M, Holland D, Day AG.

Clin J Am Soc Nephrol. 2008 Jan;3(1):105-10.

14.

Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.

Brulotte S, Sénéchal M, Poirier P, Nguyen CM, Lemieux A, Magne J, Bergeron S.

Can J Cardiol. 2007 Oct;23 Suppl B:80B-83B. Erratum in: Can J Cardiol. 2009 Mar;25(3):140.

15.

Bleeding complications in elderly patients following acute myocardial infarction.

Gill SS.

Arch Intern Med. 2005 Nov 14;165(20):2430-1. No abstract available.

PMID:
16287777
16.
17.

Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.

Porter A, Konstantino Y, Iakobishvili Z, Shachar L, Battler A, Hasdai D.

Catheter Cardiovasc Interv. 2006 Jul;68(1):56-61.

PMID:
16763985
18.

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Lee MS, Smith SD, Galor A, Hoffman GS.

Arthritis Rheum. 2006 Oct;54(10):3306-9.

19.

Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.

Delaney JA, Opatrny L, Brophy JM, Suissa S.

CMAJ. 2007 Aug 14;177(4):347-51.

20.

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.

Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators..

Eur Heart J. 2007 Sep;28(18):2200-7.

Items per page

Supplemental Content

Support Center